Multiple sclerosis research

Studies of Cortexin, Cerebrolysin, Phenotropil and Xemys, case reports from a Bemitil patent, and the history of metabolic approaches to MS.

Findings from selected studies

  • Motor scores in 63 adults with MS

    After three courses, upper-limb scores improved by 1.4 points with adjunctive Cortexin versus 0.8 with standard care alone. Lower-limb gains were 1.8 versus 0.9 points. The study did not establish an effect on relapses or disability progression.

For research and education. For decisions about MS care, consult a qualified clinician.

Findings in people with MS

The 2009 Cortexin study reported no statistically significant change in EDSS disability scores. The 2025 comparison reported gains in limb motor scores with adjunct Cortexin. The Bemitil patent describes one patient in detail who received several treatments at the same time.

The Xemys clinical and biomarker reports follow the same Phase I cohort. Disability measures were unchanged at the end of the study, and MRI activity increased temporarily. The evidence leaves effects on remyelination, relapses and long-term disability unresolved.

The Cerebrolysin comparison found no between-group difference in EDSS disability scores. The Phenotropil report assessed fatigue, mood and quality of life during adjunctive care. Most participants also received disease-modifying therapy.

2016Randomized trialEnglish abstract

[Effect of cerebrolysin on remyelination processes in multiple sclerosis patients in stage of relapse regression].

Porcine brain-derived peptide mixture; equivalence to other hydrolysates is not assumed · Journal publication

Khabirov FA, Khaybullin TI, Granatov EV, Shakirzianova SR · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

No between-group EDSS difference was reported; selected functional and neurophysiological measures differed.

Results and tables

Reported findings and study design

40 patients recovering from an MS relapse: 20 Cerebrolysin versus 20 saline after methylprednisolone 1,000 mg/day for five days. Cerebrolysin 20 mL/day for ten administrations; follow-up 3–4 weeks.

Population or model 40 patients during regression of a multiple-sclerosis relapse after steroid treatment

Dose, route and schedule

After methylprednisolone 1,000 mg/day for five days, the study used Cerebrolysin 20 mL in 200 mL saline once daily for ten administrations, compared with saline. This was sequential adjunctive treatment during recovery from an MS relapse.

Protocol source ↗ · Indexed publication abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Completed treatment17/20 (85%) versus 18/20 (90%)
Baseline age27.35 (5.65) versus 26.65 (4.93) years
Baseline disease duration29.9 (11.01) versus 30.25 (11.98) months
Baseline EDSS3.5 [2.0;4.5] versus 3.0 [1.5;4.5]
Follow-up EDSS2.0 [1.75;2.5] versus 2.5 [1.75;2.5]No significant between-group difference · p=0.665
MSFC and SDMTGreater improvement in the treated groupp=0.038 and p=0.026
Visual test comparisonNo significant differencep=0.658
Neurophysiological abnormality regression70.59% versus 27.78%p=0.028
Neurophysiological deterioration10% versus 30%p=0.228
Gadolinium-positive MRI lesions14 before versus 12 afterwardFour treated patients only

Small short-term comparison. MRI lesion counts from four treated patients cannot establish remyelination or disease modification.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
40 patients during regression of a multiple-sclerosis relapse after steroid treatment
Source reviewed
Citation and indexed abstract checked. Full methods, funding and risk of bias have not been comprehensively appraised.
Study limitations
  • Short follow-up, attrition and a very small MRI subset limit interpretation. Surrogate changes do not establish remyelination.

Reviewed 2026-09-30.

Read the source ↗
2010Uncontrolled human reportRussian-language source

Experience using Phenotropil in combined treatment of multiple sclerosis

D. V. Sazonov, O. V. Ryabukhina, E. V. Bulatova, N. A. Malkova, A. V. Babenko · Atmosfera. Nervnye bolezni. No. 4, 2010, as labeled by host

The report examines asthenia, mood and quality-of-life measures during adjunctive treatment. Most participants also received disease-modifying therapy.

Population / setting
39 patients with relapsing or secondary-progressive multiple sclerosis
Source reviewed
Original study text in a medical-portal reprint checked; publication edition not independently matched.
Study limitations
  • Uncontrolled adjunctive design; treatment contributions cannot be separated.
  • The host labels the reprint as Atmosfera, No. 4, 2010; earlier reprints circulate and edition matching remains open.

Reviewed 2026-09-29.

Read the source ↗
2009Uncontrolled human reportFull text available

Effect of Cortexin on neuroplasticity in multiple sclerosis

Format: Publisher article and Russian PDF · Reviewed: Publisher full-text results narrative and available tables checked on 1 November 2026

S. V. Kotov, T. I. Yakushina, V. Yu. Lizhdvoy · Effective Pharmacotherapy. Neurology and Psychiatry. 2009;(3):14–16

Depression and quality-of-life scores improved in an open MS cohort; the disability score did not change significantly.

Results and tables

Reported findings and study design

Depression and quality-of-life scores improved in an open MS cohort; the disability score did not change significantly.

20 adults with relapsing-remitting MS in stable remission; two ten-day courses of 10 mg intramuscular Cortexin with a two-week interval; no control group.

Population or model 20 adults with relapsing-remitting MS in stable remission; 7 men and 13 women, ages 27–43

Results · Publisher full-text results narrative and available tables checked on 1 November 2026
MeasureResultComparison, timing and statistics
Beck depression score17.6 ± 1.3 → 12.9 ± 1.4 pointsWithin-person change; 12 participants had depressive symptoms at baseline · After the treatment program · p<0.05 versus baseline
EQ-5D health score0.41 ± 0.07 → 0.73 ± 0.03Within-person change; higher score indicates better reported health · After treatment · p<0.05 versus baseline
EDSS disabilityNo significant changeParticipants entered in remission with EDSS below 3
Adverse eventsNone observed in 20 participantsSmall, short open study; not a long-term safety estimate

These results concern symptoms and quality of life in an uncontrolled cohort. Stable EDSS during a short remission-period study does not demonstrate remyelination or prevention of disease progression.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
20 adults with relapsing-remitting MS in stable remission; 7 men and 13 women, ages 27–43
Source reviewed
Publisher full-text results narrative and available tables checked on 1 November 2026
Study limitations
  • Open prospective study without a control group, randomization or blinding.
  • Participants were already in remission; stable EDSS does not demonstrate prevention of progression.
  • No adverse events were observed in this small sample; safety and disease modification are not established.

Reviewed 2026-11-01.

Read the source ↗
2025Human comparative studyFull text available

Neuropeptide immunocorrection in patients with multiple sclerosis

Cortexin tissue-derived peptide preparation

Format: Open-access journal PDF; Zenodo repository · Reviewed: Full article read; motor table visually checked

M. A. Artykova, S. A. Beknazarov · Scientific and Innovative Therapy. 2025;(2):3–9. Bukhara State Medical Institute; Zenodo deposit 5 June 2025

After three courses, the authors report upper-limb motor-score gains of 1.4 versus 0.8 points and lower-limb gains of 1.8 versus 0.9, with reported p<0.05. The proportion described as having reduced work capacity fell from 71.7% to 31.1% with adjunct Cortexin, versus 75.5% to 53.1% in controls. These are reported functional signals, not evidence of disease modification.

Results and tables

Reported findings and study design

63 adults with MS aged 18–59: standard care plus Cortexin 33 versus standard care 30; results reported after three courses.

Population or model 63 adults with MS, ages 18–59: 33 standard therapy plus Cortexin; 30 standard therapy alone

Results · Previously reviewed full-article motor table and reported work-capacity percentages
MeasureResultComparison, timing and statistics
Upper-limb motor-score gain1.4 versus 0.8 pointsp<0.05 as reported
Lower-limb motor-score gain1.8 versus 0.9 pointsp<0.05 as reported
Reduced-work-capacity proportion, add-on arm71.7% → 31.1%
Reduced-work-capacity proportion, comparison arm75.5% → 53.1%

Existing full-article extraction; the motor scale and variance are not adequately specified, and percentages lack raw counts. No MRI, relapse or EDSS progression benefit is established.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
63 adults with MS, ages 18–59: 33 standard therapy plus Cortexin; 30 standard therapy alone
Source reviewed
Methods, results, tables and references reviewed. Randomization, blinding and allocation procedures are not described; this is not classified as a randomized trial.
Study limitations
  • Small comparison with unclear allocation, baseline comparability, concomitant therapy and assessment timing; no placebo or blinding described.
  • Motor scale, variance and statistical methods are insufficiently specified. Percentages lack underlying counts; immune-marker claims have no numerical table.
  • No longitudinal MRI lesion, relapse-rate or EDSS progression outcomes are reported. Safety reporting is insufficient; this does not establish an MS treatment or replacement for disease-modifying therapy.
  • A same-title 2021 Artykova–Rakhmatov report exists; cohort overlap remains unresolved and is not counted as independent replication.

Reviewed 2026-10-03.

Read the source ↗
2006Patent / reported experimentsFull text available

Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application

Format: Patent full text · Reviewed: Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

O. V. Dorozhko, G. I. Kovalev, R. M. Salimov · RU2267319C2. Filed 15 July 2003; application published 10 February 2005; granted 10 January 2006

Example 5 describes a 47-year-old woman with MS receiving Bemitil alongside piracetam, pentoxifylline, B vitamins and massage. The patent reports improvements in strength, coordination, cognition, mood and sleep. It supplies neither a controlled MS trial nor complete results for all ten MS cases.

Results and tables

Reported patent results

Reported findings

The clinical examples describe improvement during adjunctive Bemitil treatment, without group-level efficacy scores or a controlled patient comparison.

Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.

Population or model Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.

Results · Description: Examples 3, 5 and 6; Table 3 and separate clinical group narratives.
MeasureResultComparison, timing and statistics
MS illustrative caseReported clinical/MRI remission, improved strength, coordination, memory, mood and sleepOne 47-year-old patient also receiving piracetam, pentoxifylline and vitamins · After approximately 3 weeks
Chronic-fatigue illustrative caseReported improvement in general condition, tremor, headaches, coordination and perceived weaknessOne 29-year-old patient receiving several other medicines · After a 15-day course
Animal maze experiment216.6 ± 12.1 s with Bemitil versus 304.9 ± 33.3 s after injury alone; uninjured control 224.3 ± 14 s25 mice per group; duration to exploration criterion, not a patient disability score

No aggregate MS relapse, disability-progression or MRI-lesion outcome is supplied for the 10-patient group. Selected adjunctive cases cannot establish disease modification or ME/CFS efficacy.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.
Source reviewed
The summary reflects the results reported in the cited source.
Study limitations
  • Patent assertions, not a peer-reviewed efficacy trial; multiple simultaneous interventions prevent attribution.
  • The described baseline brain MRI had no pathological changes, making a claim of MRI remission uninterpretable.
  • Animal MPTP, glutamate and haloperidol experiments are not experimental autoimmune demyelination models.

Reviewed 2026-11-06.

Read the source ↗
2016Human study · design details unresolvedFull text available

CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study

A. Belogurov Jr., K. Zakharov, Y. Lomakin, K. Surkov, S. Avtushenko, P. Kruglyakov, I. Smirnov, G. Makshakov, C. Lockshin, G. Gregoriadis, D. Genkin, A. Gabibov, E. Evdoshenko · Neurotherapeutics. 2016;13:895–904

EDSS and MRI measures were statistically unchanged at study exit. Active gadolinium-enhancing lesions increased transiently at weeks 7 and 10.

Results and tables

Reported findings and study design

Uncontrolled Phase I study; 20 MS patients enrolled at four Russian centers.

Population or model 20 MS patients enrolled at four Russian centers; open-label Phase I

Results · Source passages checked 5 November 2026; see study record for access and limitations.
MeasureResultComparison, timing and statistics
EDSS and MRI at study exitNo statistically significant change versus baseline
Active gadolinium-enhancing lesionsTransient increase at weeks 7 and 10

Small open-label study cannot establish clinical efficacy, restored tolerance or long-term safety. Early MRI activity remains relevant despite unchanged exit measures.

Source for these results ↗ · Reviewed 2026-11-05

Population / setting
20 MS patients enrolled at four Russian centers; open-label Phase I
Source reviewed
Primary publication checked for Phase I design and clinical/MRI outcomes.
Study limitations
  • Uncontrolled safety and proof-of-concept study; not evidence of reduced relapses or disability progression.
  • Early MRI activity must be considered alongside the authors’ tolerability findings.

Reviewed 2026-11-05.

Read the source ↗
2016Human study · design details unresolvedEnglish abstract

Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients

Y. Lomakin, A. Belogurov, I. Glagoleva, A. Stepanov, K. Zakharov, J. Okunola, I. Smirnov, D. Genkin, A. Gabibov · Mediators of Inflammation. 2016:2847232

The paper reports changes in circulating cytokines and chemokines after Xemys exposure.

Population / setting
Biomarker analysis from the same Phase I Xemys research program
Source reviewed
Original publisher summary checked; linked full text available.
Study limitations
  • Same clinical program as the Phase I report; not an independent efficacy trial.
  • Biomarker changes do not demonstrate restored immune tolerance or clinical disease modification.

Reviewed 2026-11-05.

Read the source ↗

The Bemitil journal article, patent and dissertation cover lupus and may share participants. Other sources describe hereditary neuromuscular conditions or experiments with cells from healthy donors.

1999Human comparative studyEnglish abstract

The effect of bemetil on production of DNA antibodies in patients with systemic lupus erythematosus

Format: Indexed English abstract · Reviewed: Abstract reviewed

T. A. Lisitsyna, A. D. Durnev, M. M. Ivanova, A. I. Speranskii, S. B. Seredenin, V. A. Nasonova · Experimental and Clinical Pharmacology. 1999;62(5):38–41. PMID 10572751

The abstract reports reduced anti-DNA antibodies and improvements in SLEDAI-1/ECLAM disease-activity measures in Bemitil-containing treatment groups. Background treatment included prednisolone, with or without cyclophosphamide. Numerical effect sizes are not available in the abstract.

Results and tables

Reported findings and study design

A four-group lupus report associated Bemitil-containing treatment with lower anti-DNA antibody levels and disease-activity scores; the abstract does not give numerical changes.

Four groups of 15, 15, 15 and 16 patients; background prednisolone with different adjuncts; eight-week assessment.

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Antibodies and lupus activityReported decreases in anti-DNA antibodies, SLEDAI-1 and ECLAM scoresNo group-level values or effect sizes in abstract
Group sizes15, 15, 15 and 16 patientsThe count spans multiple groups.
Bemitil exposure500–750 mg/day orallyEight-week comparison; the indexed background-drug dose units need original verification

Several concurrent-treatment arms prevent interpreting this as Bemitil monotherapy. Unverified background-drug units are not reproduced as dosing instructions.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
61 people with SLE; four groups of 15, 15, 15 and 16; eight-week comparison
Source reviewed
The summary reflects the results reported in the cited source.
Study limitations
  • SLE is a different disease; these findings do not establish efficacy in MS.
  • Allocation and blinding cannot be established from the abstract; concomitant therapy complicates attribution.
  • The 1997 dissertation and 2000 patent appear to describe the same research program.

Reviewed 2026-10-03.

Read the source ↗
2000Patent / reported experimentsFull text available

Method of treating systemic lupus erythematosus

Format: Russian patent with English translation · Reviewed: Original patent and numerical passages checked 5 November 2026

T. A. Lisitsyna and colleagues · RU2157684C2. Filed 22 December 1997; published 20 October 2000

The patent describes four treatment groups using glucocorticoids with or without cyclophosphamide and Bemitil. It reports improvements in selected clinical and laboratory signs and anti-DNA antibodies in the Bemitil groups. This appears to describe the same research program as the 1999 paper.

Results and tables

Reported patent results

Reported findings

The patent reports lower anti-DNA antibodies and steroid changes in adjunctive Bemitil arms of the historical lupus program; unequal groups and follow-up prevent a causal efficacy estimate.

Same 61-patient lupus program as the 1999 publication; all Bemitil arms also received glucocorticoids.

Population or model 61 SLE patients treated at the Institute of Rheumatology, 1993–1997

Results · Source passages checked 5 November 2026; see study record for access and limitations.
MeasureResultComparison, timing and statistics
Anti-DNA antibodiesReported within-group reductions in both Bemitil-containing armsp<0.001
Mean daily prednisolone, group 323.5 → 18.7 mg/day during observation
Mean daily prednisolone, group 114.7 → 29.0 mg/day during observation
Reported relapses / exacerbations11/30 without Bemitil at 6–12 months; 5/31 with Bemitil at 12–18 months

Historical treatment observations, not dosing advice. Unequal follow-up, baseline severity and treatment selection preclude a causal steroid-sparing claim or comparative relapse-risk calculation. Patent and paper are not independent replication.

Source for these results ↗ · Reviewed 2026-11-05

Population / setting
61 SLE patients treated at the Institute of Rheumatology, 1993–1997
Source reviewed
The summary reflects the results reported in the cited source.
Study limitations
  • Patent reproduction; allocation concealment and blinding are not established. Treatment choice also reflected disease severity.
  • Numerous outcomes and unequal follow-up periods prevent a simple comparative relapse-rate interpretation.
  • Not an MS study or independent confirmation of the 1999 SLE report.

Reviewed 2026-10-03.

Read the source ↗
1993Uncontrolled human reportRussian-language source

Bioenergetic disturbances and their correction in neuromuscular diseases

Format: Russian dissertation abstract, OCR reproduction · Reviewed: Author metadata and relevant text reviewed

L. A. Saikova · Doctoral dissertation author abstract. Saint Petersburg, 1993

The dissertation describes bioenergetic and enzyme-marker changes during treatment, including Bemitil comparisons. It extends the neuromuscular research context of the 1991 and 1992 publications; biochemical changes alone do not establish sustained functional benefit.

Population / setting
Neuromuscular disease research program, including hereditary muscular dystrophies
Source reviewed
The summary reflects the results reported in the cited source.
Study limitations
  • Author is Lyudmila Alekseevna Saikova; attribution to Pustozerov as dissertation author is incorrect.
  • OCR reproduction; original scan and cohort overlap with the earlier papers require reconciliation.
  • Neuromuscular disorders are not MS; heterogeneous treatments and uncontrolled observations limit inference.

Reviewed 2026-10-03.

Read the source ↗
2009In vitroRussian-language source

Inhibitory effect of 2-substituted benzimidazoles on lymphocyte mitogenesis is associated with AhR-dependent mechanisms

Format: Russian conference abstract; indexed PDF excerpt · Reviewed: Indexed abstract and table text reviewed

E. S. Sibiryak, S. V. Sadovnikov, S. V. Sibiryak · Medical Immunology. 2009;11(4–5):335. Conference abstract

At the reported Bemitil concentration, the table gives only 3±3% inhibition of mitogenesis. The combination with TCDD differed from the Bliss-model expectation. This supports an experimental interaction question, not a claim that Bemitil strongly suppresses human immunity.

Population / setting
Healthy-donor T cells stimulated with anti-CD3; benzimidazoles and TCDD interaction experiment
Source reviewed
The summary reflects the results reported in the cited source.
Study limitations
  • Conference abstract and indexed table excerpt, not a full clinical study.
  • AhR involvement is a proposed mechanism; direct receptor binding and clinical immunosuppression were not demonstrated.
  • No MS patients, demyelination outcome or clinical benefit assessment.

Reviewed 2026-10-03.

Read the source ↗

Earlier neuromuscular publications share investigators and may include some of the same participants. 1991 report ↗ · 1992 report ↗

Fatigue and metabolic approaches

The 2015 fatigue study compared Cytoflavin with a multi-drug regimen. The contribution of any individual drug in the comparison regimen remains unclear.

2015Human comparative studyFull text available

Efficacy of Cytoflavin in patients with multiple sclerosis and fatigue

Format: Publisher full text · Reviewed: Methods and results reviewed

O. A. Mialovitska · Ukrainian Medical Journal. Published 18 March 2015

The Cytoflavin group’s MFIS score fell from 45.1±4.5 to 29±4.2 (reported within-group p<0.05). The comparator regimen included pentoxifylline, piracetam, meldonium and B vitamins. The result cannot be attributed to either piracetam or meldonium.

Population / setting
62 screened; 53 with fatigue allocated to Cytoflavin (20) or conventional therapy (33)
Source reviewed
The summary reflects the results reported in the cited source.
Study limitations
  • Unequal groups; randomization and blinding are not established.
  • 62 is the screened population, not the number allocated to treatment groups.
  • A within-group change is not a demonstrated between-group effect; fatigue improvement is not disease modification.

Reviewed 2026-10-03.

Read the source ↗

Bibliography and original sources

2009 / Archival / contextual source — see review limits

Cortexin neuroplasticity in MS — original PDF

S. V. Kotov; T. I. Yakushina; V. Yu. Lizhdvoy · Effective Pharmacotherapy. Neurology and Psychiatry. (3):14–16

This publisher PDF contains the same 2009 Cortexin study summarized above.

Source record ↗

PDF ↗

1997 / Archival / contextual source — see review limits

Cyclophosphamide and Bemitil: antioxidant status and DNA integrity in SLE and rheumatoid arthritis

T. A. Lisitsyna · Dissertation author abstract; reported 23 pages

The catalogue identifies the author abstract. Participant overlap with the 1999 lupus article and 2000 patent remains uncertain.

Source record ↗

PDF ↗

1994 / Archival / contextual source — see review limits

Neuromuscular rehabilitation — publisher title/abstract mismatch

V. S. Lobzin; L. A. Saikova; V. D. Kosachev; V. G. Pustozerov; T. N. Vasilyeva · Neurology Bulletin. XXVI(1–2):51–54. DOI 10.17816/nb107044

English title describes traumatic/compressive neuropathies, but abstract concerns hereditary neuromuscular disorders. The abstract attributes more than 1,000 observations to the broader rehabilitation program. The size of the Bemitil group remains unclear.

Source record ↗

PDF ↗

1990 / Archival / contextual source — see review limits

Multiple sclerosis: metabolic disturbances and pathogenetic treatment — dissertation citation trail

Yu. N. Savchenko · Doctoral author abstract, Moscow, 36 pages; cited in later patent

A later patent cites a 36-page author abstract. Other references give 1994 and 369 pages. The original methods and results for glycine remain unavailable.

Source record ↗
1990 / Archival / contextual source — see review limits

Myelinopathies and demyelinating diseases

A. P. Khokhlov; Yu. N. Savchenko · Moscow: Meditsina. 207,[1] pages. ISBN 5-225-00726-0

The university catalogue confirms the book. The available entry supplies bibliographic information.

Source record ↗
1990 / Archival / contextual source — see review limits

Myelin metabolism paper — bibliographic reference

Associated with A. P. Khokhlov and Yu. N. Savchenko · Zhurnal Nevropatologii i Psikhiatrii. 90(8); pages reported as 104–109, conflicting citation 104–113

Secondary bibliographies give different page ranges. The original article would clarify its title, methods and findings.

Source record ↗
2004 / Archival / contextual source — see review limits

Membrane-destabilizing processes in erythrocytes of patients with multiple sclerosis

A. A. Sokolova · Candidate medical dissertation, Kazan

Dissertation reproduction describes membrane and oxidative-stress research. Biomarker associations do not establish efficacy of Bemitil or another treatment.

Source record ↗
2000 / Archival / contextual source — see review limits

Historical Russian methodological recommendations No. 2000/166

Russian Ministry of Health · 17 November 2000; reproduced document

This historical guidance lists piracetam and Cerebrolysin among adjunct treatments.

Source record ↗
2005 / Archival / contextual source — see review limits

Historical multiple-sclerosis management protocol

Russian clinical protocol · 18 April 2005

Nootropic adjuncts, including piracetam and Cerebrolysin, appear with grade-C evidence. This historical recommendation does not establish modern clinical efficacy.

Source record ↗
2007 / Archival / contextual source — see review limits

Marketing research on medicine provision for people with MS in Tyumen

O. V. Kolenchik · Dissertation, 114 pages

The catalogue and excerpts describe prescribing patterns in Tyumen. The full dissertation is needed to verify utilization figures.

Source record ↗
2018 / Archival / contextual source — see review limits

Prospects of metabolic therapy in multiple sclerosis

G. N. Bisaga · Third RUCTRIMS congress abstract

The congress abstract discusses metabolic approaches and acknowledges the limited clinical evidence.

Source record ↗
1998 / Archival / contextual source — see review limits

Study of DNA damage of blood mononuclear cells in SLE by DNA-comets

See indexed author list · PMID 9532374

The indexed record concerns DNA damage in lupus. Bemitil exposure is unconfirmed.

Source record ↗

Open questions in the evidence

Stroke research ↗ · Autoimmune research ↗ · Complete bibliography ↗ · Research map ↗